Remedy Plan Therapeutics Raises $18 Million Financing to Accelerate Advancement of Lead Asset RPT1G into Phase 1/2 Trials
Parisa Moghaddam-Taaheri on May 1, 2025 in Media
Remedy Plan
Remedy Plan Therapeutics Initiates Dosing in Phase 1 Clinical Trial of RPT1G, a First-In-Class Hyperbolic NAMPT Inhibitor
Parisa Moghaddam-Taaheri on December 1, 2024 in Media
UPDATE - Remedy Plan Therapeutics Showcases Preclinical Data from First-In-Class NAMPT Inhibitor, RPT1G, Demonstrating Synergy with BCL-2 Family Inhibitors in AML at the 2024 ASH Annual Meeting
Parisa Moghaddam-Taaheri on December 1, 2024 in Media
Remedy Plan Therapeutics Announces Presentation at the 66th American Society of Hematology (ASH) Annual Meeting
Parisa Moghaddam-Taaheri on November 1, 2024 in Media
Remedy Plan Therapeutics Showcases Novel NAMPT Inhibitor During Podium Presentation at the 42nd Annual J.P. Morgan Healthcare Conference
Parisa Moghaddam-Taaheri on January 1, 2024 in Media